Analysts Anticipate Zimmer Biomet Holdings Inc (ZBH) to Announce $1.86 EPS

Equities research analysts expect that Zimmer Biomet Holdings Inc (NYSE:ZBH) will report earnings of $1.86 per share for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have made estimates for Zimmer Biomet’s earnings, with estimates ranging from $1.83 to $1.94. Zimmer Biomet posted earnings of $1.91 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 2.6%. The company is scheduled to announce its next quarterly earnings results before the market opens on Friday, April 26th.

On average, analysts expect that Zimmer Biomet will report full year earnings of $7.81 per share for the current financial year, with EPS estimates ranging from $7.75 to $7.85. For the next fiscal year, analysts anticipate that the business will post earnings of $8.35 per share, with EPS estimates ranging from $8.21 to $8.46. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Friday, February 1st. The medical equipment provider reported $2.18 EPS for the quarter, meeting analysts’ consensus estimates of $2.18. The company had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a positive return on equity of 13.17% and a negative net margin of 4.78%. Zimmer Biomet’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.10 earnings per share.

ZBH has been the subject of a number of research reports. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a research report on Saturday, April 13th. Citigroup upgraded Zimmer Biomet from a “neutral” rating to a “buy” rating and upped their price objective for the company from $122.00 to $127.00 in a research report on Wednesday, January 2nd. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price objective for the company in a research report on Monday, April 8th. Stifel Nicolaus reduced their price objective on Zimmer Biomet from $150.00 to $135.00 and set a “buy” rating for the company in a research report on Tuesday, January 22nd. Finally, Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Saturday, February 2nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $129.95.

Zimmer Biomet stock traded up $0.31 during mid-day trading on Friday, reaching $120.00. 1,423,091 shares of the stock traded hands, compared to its average volume of 1,262,516. The stock has a market cap of $24.55 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 2.25 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.90 and a current ratio of 1.83. Zimmer Biomet has a 12-month low of $96.99 and a 12-month high of $134.55.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Thursday, March 28th. Zimmer Biomet’s dividend payout ratio is presently 12.57%.

In related news, Director Betsy J. Bernard purchased 4,250 shares of the business’s stock in a transaction on Wednesday, February 6th. The stock was acquired at an average price of $117.41 per share, with a total value of $498,992.50. Following the completion of the acquisition, the director now owns 2,000 shares of the company’s stock, valued at approximately $234,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Syed A. Jafry purchased 1,925 shares of the business’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $125.52 per share, with a total value of $241,626.00. The disclosure for this purchase can be found here. Insiders have acquired 12,860 shares of company stock valued at $1,548,994 in the last three months. 0.72% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Selway Asset Management boosted its stake in shares of Zimmer Biomet by 5.7% in the first quarter. Selway Asset Management now owns 29,180 shares of the medical equipment provider’s stock worth $3,726,000 after acquiring an additional 1,586 shares during the period. Gulf International Bank UK Ltd boosted its stake in shares of Zimmer Biomet by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 48,301 shares of the medical equipment provider’s stock worth $6,168,000 after acquiring an additional 643 shares during the period. IFM Investors Pty Ltd boosted its stake in shares of Zimmer Biomet by 9.4% in the first quarter. IFM Investors Pty Ltd now owns 12,825 shares of the medical equipment provider’s stock worth $1,638,000 after acquiring an additional 1,098 shares during the period. Wedbush Securities Inc. boosted its stake in shares of Zimmer Biomet by 4.0% in the first quarter. Wedbush Securities Inc. now owns 3,039 shares of the medical equipment provider’s stock worth $388,000 after acquiring an additional 117 shares during the period. Finally, FNY Investment Advisers LLC bought a new position in shares of Zimmer Biomet in the first quarter worth about $54,000. 89.82% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.